BiotechTube

DONQ52 + Placebo

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Celiac Disease

Conditions

Celiac Disease

Trial Timeline

Sep 19, 2022 → Jan 17, 2025

NCT ID
NCT05425446

About DONQ52 + Placebo

DONQ52 + Placebo is a phase 1 stage product being developed by Chugai Pharmaceutical for Celiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05425446. Target conditions include Celiac Disease.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05425446Phase 1Completed

Competing Products

17 competing products in Celiac Disease

See all competitors
ProductCompanyStageHype Score
Placebo DONQ52 + DONQ52Chugai PharmaceuticalPhase 2
42
Placebo + RO5459072RochePhase 1
29
CCX282-B + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714 + PlaceboAmgenPhase 2
35
AMG 714AmgenPre-clinical
26
KAN-101 + PlaceboPfizerPhase 2
35
Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part CPfizerPhase 1/2
24
Ritlecitinib + PlaceboPfizerPhase 2
42
PRV-015SanofiPhase 2
35
TIMP-GLIATakeda PharmaceuticalPhase 1
29
TIMP-GLIA + PlaceboTakeda PharmaceuticalPhase 2
35
PTG-100 + PlaceboProtagonist TherapeuticsPhase 1
26
Rifaximin + PlaceboBausch HealthPre-clinical
20
LatiglutenaseAllergy TherapeuticsPhase 2
21
BL-7010 + PlaceboBioLineRxPhase 1/2
22
VTP-1000Barinthus BiotherapeuticsPhase 1
26